Micron Technology Reports Strong Fiscal First Quarter

Micron Technology has delivered an impressive outlook for the current quarter, surpassing expectations with a sharp increase in revenue. The memory-chip manufacturer attributes this success to robust pricing and the growing demand for chips used in artificial intelligence applications. Despite expectations of a loss, Micron Technology reported a narrower-than-expected deficit. As a result, shares surged by 4.3% after-hours, reaching $82.11.

Warner Bros. Discovery and Paramount Explore Potential Merger

Recently, Warner Bros. Discovery Chief Executive David Zaslav and Paramount CEO Bob Bakish held discussions regarding a potential merger between the two companies. Although there have been no formal negotiations at this point, their meeting has sparked speculation about a possible collaboration. Following the news, Warner Bros. Discovery shares experienced a slight decline of 1.6% after-hours, while Paramount shares sank 1.7%.

Calliditas Therapeutics Receives FDA Approval for Tarpeyo

Calliditas Therapeutics has achieved full approval from the U.S. Food and Drug Administration (FDA) for its treatment, Tarpeyo, developed for patients diagnosed with primary immunoglobulin A nephropathy (IgAN) - a kidney disease. This marks a significant milestone as Tarpeyo becomes the first FDA-approved treatment specifically designed for IgAN patients, offering a measure of kidney function improvement. Consequently, shares soared by 25% after-hours, amounting to $28.